CN1136839C - 速效皮炎湿疹膏 - Google Patents
速效皮炎湿疹膏 Download PDFInfo
- Publication number
- CN1136839C CN1136839C CNB021194092A CN02119409A CN1136839C CN 1136839 C CN1136839 C CN 1136839C CN B021194092 A CNB021194092 A CN B021194092A CN 02119409 A CN02119409 A CN 02119409A CN 1136839 C CN1136839 C CN 1136839C
- Authority
- CN
- China
- Prior art keywords
- ointment
- eczema
- dermatitis
- quick
- acting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002674 ointment Substances 0.000 title claims abstract description 40
- 206010012435 Dermatitis and eczema Diseases 0.000 title claims abstract description 7
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims abstract description 20
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims abstract description 11
- 229960004618 prednisone Drugs 0.000 claims abstract description 11
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims abstract description 10
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 claims abstract description 10
- 229960001138 acetylsalicylic acid Drugs 0.000 claims abstract description 10
- 229960003291 chlorphenamine Drugs 0.000 claims abstract description 10
- 229960004022 clotrimazole Drugs 0.000 claims abstract description 10
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229960003276 erythromycin Drugs 0.000 claims abstract description 10
- 229960000282 metronidazole Drugs 0.000 claims abstract description 10
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims abstract description 10
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 claims abstract description 10
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 claims description 9
- 229940098166 bactrim Drugs 0.000 claims description 9
- 229960000785 fluocinonide Drugs 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 abstract description 24
- 208000010668 atopic eczema Diseases 0.000 abstract description 9
- 238000011282 treatment Methods 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 7
- 206010048768 Dermatosis Diseases 0.000 abstract description 6
- 208000017520 skin disease Diseases 0.000 abstract description 6
- 230000003115 biocidal effect Effects 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 abstract description 2
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 abstract 1
- 229960005404 sulfamethoxazole Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 17
- 206010040882 skin lesion Diseases 0.000 description 12
- 231100000444 skin lesion Toxicity 0.000 description 12
- 206010021531 Impetigo Diseases 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 206010012442 Dermatitis contact Diseases 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 208000010247 contact dermatitis Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000002804 anti-anaphylactic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000004026 tunica intima Anatomy 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种由复方新诺明、强的松、扑尔敏、甲硝唑、阿司匹林、红霉素软膏、1%克霉唑软膏、肤轻松软膏组成的速效皮炎湿疹膏,将它外涂于患处可对各种皮炎、湿疹、脓疱疮等严重皮肤病有病因、病根并发症三向治疗作用,具有起效迅速、治疗时间短、抗菌广谱、根治率高的特点,临床证明,3天内的总治愈率可达95%以上。
Description
一、技术领域:本发明涉及一种西药组合外用药,具体涉及一种用于治疗各种皮炎、湿疹、脓疱疮的外用药膏。
二、背景技术:尿布皮炎、接触性皮炎、异位性皮炎、湿疹样皮炎等各种皮炎,急性、亚急性、慢性湿疹,脓疱疮等是皮肤科常见多发病。现有的外用药如皮炎平、皮康王等治疗上述皮肤病很难达到病因、病根、并发症三向全面的治疗作用,对于上述皮肤病轻微类型可能有治疗效果,但对严重皮损患者显得药轻病重,对某些皮肤病可能无效。
三、发明内容:本发明所要解决的技术问题是提供一种外涂于患处并对各种皮炎、湿疹、脓疱疮等严重皮肤病有病因、病根并发症三向治疗作用的速效皮炎湿疹膏。
为解决上技术述问题,本发明速效皮炎湿疹膏的成份为:
复方新诺明 4-5g 强的松 0.04-0.055g
扑尔敏 0.035-0.045g 甲硝唑 1.6-2.4g
阿司匹林 2.8-3.2g 红霉素软膏 9-11g
1%克霉唑软膏 9-11g 肤轻松软膏 9-11g
本发明药物优选的配比为:
复方新诺明 4.8g 强的松 0.05g
扑尔敏 0.04g 甲硝唑 2g
阿司匹林 3g 红霉素软膏 10g
1%克霉唑软膏 10g 肤轻松软膏 10g
药物的浓度与皮损面积成反比,皮损面积越大,药物的浓度宜稍低为好,皮损面积越小,药物的浓度宜稍高为好,因此,除强的松外,可以考虑在标准剂量基础上加减50%剂量而软膏剂量不变,但不利于推广应用。标准剂量具有通用性能基本应答皮肤病的临床多样性。
本发明的药物很容易制备,只需将上述前五种共研为末拌入后三种软膏内即可。
本发明的用法是:每日三次于皮损处涂抹。对于脓疱疮或继发细菌感染者可在医生指导下使用抗生素内科治疗,本品不必停用,但禁止本品中同类药物的口服或注射。
本发明药物中的阿司匹林具有抗凝作用,肤轻松软膏、强的松具有抗炎作用,复方新诺明、甲硝唑、红霉素软膏具有抗广谱菌和抗化脓菌感染的作用,扑尔敏具有抗变态反应作用,克霉唑软膏能有效地防止真菌感染。各种皮炎、湿疹大多与变态反应有关,脓疱疮发病与细菌感染有关,二者病因不同,但都可以使机体产生免疫反应,都可以统一到炎症病理上来,结果都大同小异,都会使受损组织形成变质、渗出、增生性病灶和病灶区血液循环障碍及由它们所产生的炎性分泌物,这种由炎症形成的病理性病灶就是病根。由于皮损启动的凝血机制和机体本身存在的抗凝机制是同时存在对立统一的,当前者为主要矛盾时就要启动后者。受损血管附近健康的血管有强大的新陈代谢能力,有正常的抗凝机制。如果受损血管用某种药物启动其抗凝机制尽管比较有限,但该血管受其附近健康的促进能渐渐恢复其循环功能,进而恢复新陈代谢,促进病灶中变性分泌物的吸收,恢复病灶的供血供氧,与此同时,抑制变质渗出增生、抑制炎症细胞向炎区募集和在血管内膜的粘附、稳定溶酶体膜、抑制肉芽组织增生、抑制变态反应,使药理学符合病因病根双向治疗的效果。大多数皮肤病皮损不单一,有的部位如渗液、破溃、糜烂、流脓等是细菌感染的高发区,而抗生素和抑制免疫作用的药物等又能促进真菌感染适当的预防会有利用病灶的康复。因此,本发明具有起效迅速、治疗时间短、抗菌广谱、根治率高的特点,临床证明,3天内的总治愈率可达95%以上。
本发明对尿布皮炎80例,接触性皮炎170例,异位性皮炎85例,湿疹样皮炎75例,湿疹60例,脓疱疮130例作了临床试验,其疗效如表1所示:
表1 临床试验结果
| 病类 | 总例数(例) | 治疗天数(天) | 治愈例数(例) | 治愈率% |
| 尿布皮炎 | 80 | 3 | 77 | 96 |
| 接触性皮炎 | 170 | 3 | 165 | 97 |
| 异位性皮炎 | 85 | 3 | 80 | 94 |
| 湿疹样皮炎 | 75 | 3 | 69 | 92 |
| 湿疹 | 60 | 3 | 54 | 90 |
| 脓疱疮 | 130 | 3 | 128 | 98 |
表1中的治疗效果是以三天为一个阶段观察疗效,治愈是以体症消失,皮损消退90%以上为治愈标准。
本发明的药物几乎没有毒副作用,其原因是:
1、免疫反应是全身反应,注射和口服给药是全身性给药,本方仅限外用,其目的是恢复病灶新陈代谢,发挥局部抗过敏的作用,对免疫反应影响较小。
2、当病灶新陈代谢障碍时,不进入血液循环,没有抗免疫性。当新陈代谢逐渐恢复时,逐渐进入血液循环,有一定的抗免疫性。由不进入血液循环到慢慢进入血液循环,符合递增给药原则。但因为本品速效,从好转到痊愈的时间极短,对免疫反应的影响还是较小的。
3、如果是100%体表面积严重皮损者,本品使用量仅为三分之一,可能有一定药物进入血液循环,但对于严重皮损者适当的抗免有益无害。
4、根据临床观察皮损并非同一时间痊愈,痊愈的部位停止用药,符合递减停药的原则。
5、小儿用药符合按体表面积给药的原则。
6、对于皮损面积超过90%以上,建议以脐为界,第一次用于上半身,第二次用于下半身,交替用药。
四、具体实施方式:
实施例1
复方新诺明4g 强的松0.04g 扑尔敏0.035g
甲硝唑1.6g 阿司匹林2.8g 红霉素软膏9g
1%克霉唑软膏9g 肤轻松软膏9g
实施例2
复方新诺明5g 强的松0.055g 扑尔敏0.045g
甲硝唑2.4g 阿司匹林3.2g 红霉素软膏11g
1%克霉唑软膏11g 肤轻松软膏11g
实施例3
复方新诺明4.8g 强的松0.05g 扑尔敏0.04g
甲硝唑2g 阿司匹林3g 红霉素软膏10g
1%克霉唑软膏10g 肤轻松软膏10g
以上三种实施例的配制方法如下:
先将复方新诺明、强的松、扑尔敏、甲硝唑、阿司匹林混合后研末,再掺入红霉素软膏、1%克霉唑软膏、肤轻松软膏中调合均匀即可。
Claims (2)
1、一种速效皮炎湿疹膏,其成份为:
复方新诺明 4-5g 强的松 0.04-0.055g
扑尔敏 0.035-0.045g 甲硝唑 1.6-2.4g
阿司匹林 2.8-3.2g 红霉素软膏 9-11g
1%克霉唑软膏 9-11g 肤轻松软膏 9-11g
2、根据权利要求1所说的速效皮炎湿疹膏,其特征是配比为:
复方新诺明 4.8g 强的松 0.05g
扑尔敏 0.04g 甲硝唑 2g
阿司匹林 3g 红霉素软膏 10g
1%克霉唑软膏 10g 肤轻松软膏 10g
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021194092A CN1136839C (zh) | 2002-05-15 | 2002-05-15 | 速效皮炎湿疹膏 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021194092A CN1136839C (zh) | 2002-05-15 | 2002-05-15 | 速效皮炎湿疹膏 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1382447A CN1382447A (zh) | 2002-12-04 |
| CN1136839C true CN1136839C (zh) | 2004-02-04 |
Family
ID=4744682
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021194092A Expired - Fee Related CN1136839C (zh) | 2002-05-15 | 2002-05-15 | 速效皮炎湿疹膏 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1136839C (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101229180B (zh) * | 2007-01-23 | 2011-04-20 | 吴金霞 | 一种治疗褥疮的组合药物 |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4791682B2 (ja) * | 2003-02-21 | 2011-10-12 | 帝國製薬株式会社 | 痔疾患用治療剤 |
| CN1299687C (zh) * | 2004-11-16 | 2007-02-14 | 王东臣 | 一种治疗静脉损伤的软膏 |
| CN102000093A (zh) * | 2010-11-05 | 2011-04-06 | 刘志稳 | 一种治疗脓疱疮外用软膏 |
| CN108498419A (zh) * | 2018-05-03 | 2018-09-07 | 天津炫盛科技开发有限公司 | 祛斑膏及其制备方法 |
| CN108524537A (zh) * | 2018-06-27 | 2018-09-14 | 赵怀邦 | 一种炎净散软膏 |
-
2002
- 2002-05-15 CN CNB021194092A patent/CN1136839C/zh not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101229180B (zh) * | 2007-01-23 | 2011-04-20 | 吴金霞 | 一种治疗褥疮的组合药物 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1382447A (zh) | 2002-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Larijani et al. | Effects of intravenous Semelil (ANGIPARSTM) on diabetic foot ulcers healing: A multicenter clinical trial | |
| HK1224206A1 (zh) | 用於治疗红斑痤疮或红脸相关皮肤病的含黄连素或其类似物的组合物 | |
| AU2007280625B2 (en) | Use of escin | |
| CN1136839C (zh) | 速效皮炎湿疹膏 | |
| CN113274384B (zh) | 驴食草酚在制备防治溃疡性结肠炎的药物中的应用及其药物 | |
| Samarh et al. | Evidence based medical use of aloe vera extracts, short review of literature | |
| Bahrami et al. | Clinical application of oral form of ANGIPARS™ and in combination with topical form as a new treatment for diabetic foot ulcers: A randomized clinical trial | |
| CN102846666B (zh) | 物理改性后的中华眼镜蛇蛇毒在制备治疗急、慢性肾病的药物中的用途 | |
| US20240366550A1 (en) | Drug for Treating Prostatitis or Benign Prostatic Hyperplasia (BPH) | |
| JP2001089382A (ja) | 早期血管再生及び低分子量ヘパリン投与による不安定冠動脈疾患の治療方法 | |
| Cecchi et al. | Successful treatment of localized pyoderma gangrenosum with topical pimecrolimus | |
| CN1120721C (zh) | 治疗痔疮的外用药膏 | |
| Oh et al. | Acute interstitial nephritis induced by Solanum nigrum | |
| CN1381259A (zh) | 一种治疗直肠、肛门疾病的药物 | |
| CN117899149A (zh) | 一种防治糖尿病皮肤溃疡的组合物及其制备方法与应用 | |
| CN105079788A (zh) | 一种治疗放射性直肠炎的配方 | |
| CN108635362B (zh) | 一种治疗糖尿病足的药物组合物 | |
| CN1167430C (zh) | 一种广谱抗菌治疗深度烧烫伤的药膏 | |
| CN105395975A (zh) | 一种治疗溃疡性结肠炎的灌肠中药组合物及其制备方法 | |
| RU2133610C1 (ru) | Способ лечения псориатической эритродермии | |
| CN1164291C (zh) | 治疗腰椎间盘突出症的中成药及制备方法 | |
| CN102266408A (zh) | 一种干预皮肤瘙痒的中药制剂及其制备方法 | |
| CN103251627B (zh) | 甘珀酸或其盐在制备治疗炎症性疾病的药物中的应用 | |
| Hui et al. | A rare case of propofol-induced acute hepatitis in after a brief endoscopic retrograde cholangio-pancreatography (ERCP) | |
| CN1171622C (zh) | 一种治疗皮肤病的药物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040204 Termination date: 20140515 |